4 Of The Best Income Stocks Around: GlaxoSmithKline plc, Standard Life Plc, SSE PLC And Centrica plc

GlaxoSmithKline plc (LON: GSK), Standard Life Plc (LON: SL), SSE PLC (LON: SSE) and Centrica PLC (LON:CNA) are four of the best dividend plays around.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Standard Life (LSE: SL) has transformed itself into an income champion over the past five years. The company’s shift to a fee-based business model has led to a tripling of cash flow generated from operations since 2010. Assets under management have risen by 50% over the same period. 

This growth has helped support the company’s dividend payout growth. Since 2011 Standard’s dividend payout has increased at a steady rate of 7% per annum. Since 2010 Standard Life has returned 147p per share to investors, including the recent special dividend and over five years the shares have produced a total return of 180%. Based on the estimated growth of the UK pension market, the next five years could see a similar performance. 

Standard Life trades at a forward P/E of 16.8 and supports a yield of 4.6%. Earnings per share are predicted to grow by 48% this year. 

Dividend concerns 

GlaxoSmithKline’s (LSE: GSK) shares have sunk to a four-year low on fears about the sustainability of the company’s dividend payout. However, to a certain extent, these concerns are unfounded.

Management has stated that the company’s dividend of 80p per share is safe for the next three years. A special dividend of 20p per share payable during the fourth quarter will take the total payout for 2015 to 100p per share, a yield of 7.9% based on Glaxo’s current share price. 

Glaxo currently trades at a forward P/E of 16.9 and supports a yield of 7.2%. Earnings per share are predicted to shrink by 21% this year. 

Slow and steady 

Last year, SSE (LSE: SSE) made a commitment to target an increase in the full-year dividend for 2015/16 of at least RPI inflation, with annual increases thereafter of at least RPI inflation also being targeted.

This is hardly the most impressive dividend policy. The RPI measure of inflation has averaged 1% this year, so investors won’t see much in the way of a dividend increase at all. 

Nevertheless, for the conservative dividend investor SSE’s dividend policy is ideal. The payout is covered 1.2 times by earnings per share and due to the nature of SSE’s business, the company has a certain degree of clarity over its revenue streams. As a result, it’s unlikely management will suddenly take an axe to the dividend. 

SSE currently trades at a forward P/E of 12.6 and supports a yield of 6.2%. Earnings per share are predicted to shrink by 10% this year.

Changing business model 

Centrica (LSE: CNA) has already cut its dividend payout once this year. However, according to City projections the new, lower payout is now covered one-and-a-half times by earnings per share, leaving plenty of room for manoeuvre. 

What’s more, management’s recent decision to scale back Centrica’s upstream business is a great move for the company. Oil & gas production is a notoriously volatile and capital intensive business. Focusing on the more predictable customer-facing side of the business should put Centrica back on the path to long-term sustainable growth.

Also, Centrica’s focus on the more predictable customer side of the business should help the company maintain and increase its dividend over time.  

Centrica currently trades at a forward P/E of 12.5 and supports a yield of 5.4%. Earnings per share are predicted to shrink by 7% this year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended Centrica and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

A lot of people use Trustpilot, but should I trust the investment for my Stocks & Shares ISA?

Oliver thinks Trustpilot offers a potentially high-growth opportunity for his Stocks and Shares ISA. But he's noticed some risks, too.

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

How the IDS share price could leap 15%+ from here

On Wednesday, 17 April, the IDS share price soared as news of a takeover bid hit newswires. This offer has…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

2 overlooked cheap shares I’m tipping to eventually soar

These two cheap shares may not be obvious bargains, but our writer explains the investment case behind buying them for…

Read more »

Investing Articles

1 no-brainer pick I’d love to buy for my Stocks & Shares ISA!

A Stocks & Shares ISA is a great investment vehicle for our writer. Here she explains why, and one stock…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Just released: our 3 best dividend-focused stocks to buy before May [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Will the Rolls-Royce share price keep rising in 2024?

With the Rolls-Royce share price going on a surge, this Fool wants to look forward to where it could potentially…

Read more »

Investing Articles

£10k in an ISA? Here’s how I’d target a regular £30k+ second income stream

Reliable dividends can help provide a lot more financial freedom. Here's how I'd aim for a substantial second income inside…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Lloyds share price hanging on to 50p ahead of Wednesday’s Q1 earnings report. Where to now?

Down in April and with low earnings expected this week, Mark David Hartley investigates where the Lloyds share price might…

Read more »